Imiquimod for the treatment of genital warts a review of clinical effectiveness and cost-effectiveness
The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) compared to other treatment modalities for the treatment of genital warts (GW). This report is the third in the series of three reports on IMQ. The previous two reports were on IMQ for the t...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, September 25, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) compared to other treatment modalities for the treatment of genital warts (GW). This report is the third in the series of three reports on IMQ. The previous two reports were on IMQ for the treatment of basal cell and squamous carcinoma, and actinic keratosis |
|---|---|
| Physical Description: | 1 PDF file (28 pages) illustrations |